Long-term milrinone therapy is common in patients with advanced heart failure awaiting transplant, although there is evidence that long-term administration of inotropic therapy increases mortality ...
Type 3 phosphodiesterase inhibitors other than cilostazol, such as milrinone, have been associated with increased mortality in patients with heart failure. Cilostazol has fewer inotropic effects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback